Eli Lilly in talks to acquire cancer biotech Scorpion Therapeutics for $2.5 billion, with potential milestone payments.

Barclays says reports of Eli Lilly (LLY) reportedly being in talks to acquire Scorpion Therapeutics has a positive read-through to Relay ...

Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers ...

Eli Lilly (LLY) is in advanced talks to buy cancer-focused biotech Scorpion Therapeutics in a deal worth up to $2.5B, people close to the talks ...

The mergers and acquisitions market has already seen a flurry of deals at the start of 2025 across sectors. Here's a look at ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...

As top pharma executives arrive in San Francisco, CA, to attend the J.P. Morgan Healthcare Conference next week, biotech ...

The Business Journal has the list of the Massachusetts biotech companies that raised the largest venture capital rounds in the last year. Meet the most-capitalized companies of 2024.

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in ...

Eli Lilly and venture capital firm Andreessen Horowitz (a16z) are joining forces to create a unique new fund dubbed the ...

Eli Lilly's popular obesity drug Zepbound can now be covered by government-backed Medicare drug plans, CNBC reported on ...